AHA 2024: Zerlasiran shows promising Phase II results for elevated lipoprotein(a)
Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...
AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein(a)
"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...
Daily58m
LDL-C and lipoprotein(a) levels independently and additively associated with ASCVD risk: Study
The results of a recent study that was published in the journal of Circulation, suggest that low-density lipoprotein ...
FierceBiotech5d
Lilly's lipoprotein-blocking heart med posts midstage win, turning up heat on potential AZ showdown
A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...
Daily58m
Elevated Remnant Cholesterol tied to increased ASCVD events in Individuals With Diabetes: Study
Elevated Remnant Cholesterol tied to increased ASCVD events in Individuals With Diabetes suggests a study published in the ...
I went on a vegan diet and my cholesterol went up — here’s why
For those choosing to go vegan, the doctor said, it’s important to “increase soluble fiber, focus on whole foods, which are ...
STAT5d
Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...
Zacks.com on MSN4d
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns ...
Eli Lilly's Lipoprotein(a) Treatment Muvalaplin Meets Primary Endpoint in Trial
Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a ...
Morningstar6d
Eli Lilly's Lipoprotein(a) Treatment Muvalaplin Meets Primary Endpoint in Trial
Eli Lilly said a Phase 2 clinical trial for its treatment to inhibit lipoprotein(a) formation met its primary endpoint. Eli Lilly said the treatment, a once-daily pill called muvalaplin ...